Last reviewed · How we verify
Proximod
Proximod is a Small molecule drug developed by Longevity Inc.. It is currently in Phase 1 development. Also known as: IMM-H001.
Proximod is being studied in a Phase 2 trial for the treatment of moderate-to-severe active Rheumatoid Arthritis. The trial is evaluating the efficacy of proximod at doses of 5mg and 10mg daily, as well as a single intervention of proximod.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Proximod |
|---|---|
| Also known as | IMM-H001 |
| Sponsor | Longevity Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial. (PHASE2)
- Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis (PHASE1)
- Proximod Pharmacokinetics In Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Proximod CI brief — competitive landscape report
- Proximod updates RSS · CI watch RSS
- Longevity Inc. portfolio CI
Frequently asked questions about Proximod
What is Proximod?
Who makes Proximod?
Is Proximod also known as anything else?
What development phase is Proximod in?
Related
- Manufacturer: Longevity Inc. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: IMM-H001
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing